Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageBridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases. We seek to translate advances in genetic science into therapies for patient populations with significant unmet medical needs. Since our founding 10 years ago, we have advanced multiple programs from discovery through regulatory approval and commercialization.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Business segments
Q2 2026 · $38.8MThe company’s own SEC segment disclosure.
- License Services And Royalty$17.6M45%
- Royalty$15.4M40%
- License And Service$5.8M15%
BridgeBio Pharma, Inc. (BBIO) reported revenue of $244M in Q2 2026 (quarter ended June 30, 2026), up 120% from the same quarter a year earlier. That came with a gross margin of 94% and net loss of $156M. For the full year FY2025, revenue was $502M (+126% year on year) and net income −$733M. Its largest product in 2026-Q2 was License Services And Royalty at $18M, 45% of the disclosed total, just ahead of Royalty at 40%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.